Medpace’s (MEDP) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Medpace (NASDAQ:MEDP) in a research report report published on Tuesday, Benzinga reports. William Blair also issued estimates for Medpace’s FY2024 earnings at $11.83 EPS, Q1 2025 earnings at $2.92 EPS, Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.19 EPS and FY2025 earnings at $12.35 EPS.

A number of other equities research analysts also recently weighed in on MEDP. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Deutsche Bank Aktiengesellschaft reduced their target price on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a report on Wednesday, July 24th. Robert W. Baird reduced their target price on Medpace from $430.00 to $413.00 and set an “outperform” rating on the stock in a report on Friday, September 20th. Redburn Atlantic began coverage on Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. Finally, Guggenheim reduced their target price on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $380.00.

Medpace Trading Down 0.6 %

NASDAQ MEDP opened at $328.08 on Tuesday. The stock’s 50 day moving average is $352.59 and its two-hundred day moving average is $381.83. The company has a market capitalization of $10.16 billion, a price-to-earnings ratio of 33.44, a PEG ratio of 1.77 and a beta of 1.35. Medpace has a 1-year low of $239.00 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. The company had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.22 earnings per share. On average, analysts predict that Medpace will post 11.64 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Signaturefd LLC increased its holdings in shares of Medpace by 4.9% in the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock worth $230,000 after acquiring an additional 26 shares in the last quarter. Wealth Alliance increased its holdings in shares of Medpace by 2.9% in the second quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after acquiring an additional 27 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Medpace by 0.7% in the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after acquiring an additional 32 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Medpace by 5.3% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock worth $316,000 after acquiring an additional 39 shares in the last quarter. Finally, Journey Advisory Group LLC increased its holdings in shares of Medpace by 1.9% in the second quarter. Journey Advisory Group LLC now owns 2,390 shares of the company’s stock worth $984,000 after acquiring an additional 44 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.